How Rhapsido’s symptomatic dermographism approval expands Novartis immunology strategy
Novartis’ Rhapsido won the first FDA label for symptomatic dermographism after a 29.3% complete response in Phase 3 RemIND.
Pharma & Biotech
Features & Analysis
Rhapsido doubles complete hive response rate as Novartis secures new FDA indication
FDA approves Novartis Rhapsido as the first treatment specifically for symptomatic dermographism after positive Phase III RemIND results.
Pharma & Biotech
Roche cuts MS relapses up to 58.5% with fenebrutinib as FDA weighs an oral rival to its own Ocrevus
The FDA has accepted Roche’s fenebrutinib filing under Priority Review for both relapsing and primary progressive multiple sclerosis, potentially creating a high-efficacy oral alternative across disease forms currently treated very differently.
Pharma & Biotech
Novartis’ remibrutinib wins two Phase 3 multiple sclerosis trials as BTK strategy gets a crucial lift
Remibrutinib beat teriflunomide on relapse rates and every key secondary endpoint across the Phase 3 REMODEL studies, while avoiding the liver-safety signal that has complicated development of other BTK inhibitors.
Pharma & Biotech
Novartis remibrutinib beats teriflunomide in two Phase 3 multiple sclerosis trials
Novartis says oral BTK inhibitor remibrutinib significantly reduced relapse rates and MRI lesions versus teriflunomide in both Phase 3 REMODEL trials, with no liver safety signal and global regulatory filings now planned.